{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Thérapie aversive : Questions médicales les plus fréquentes",
"headline": "Thérapie aversive : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Thérapie aversive : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Thérapie aversive"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thérapie comportementale",
"url": "https://questionsmedicales.fr/mesh/D001521",
"about": {
"@type": "MedicalCondition",
"name": "Thérapie comportementale",
"code": {
"@type": "MedicalCode",
"code": "D001521",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F04.754.137"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Thérapie aversive",
"alternateName": "Aversive Therapy",
"code": {
"@type": "MedicalCode",
"code": "D001348",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Morten Moshagen",
"url": "https://questionsmedicales.fr/author/Morten%20Moshagen",
"affiliation": {
"@type": "Organization",
"name": "Ulm University, Albert-Einstein-Allee 47, 89081, Ulm, Germany."
}
},
{
"@type": "Person",
"name": "Benjamin E Hilbig",
"url": "https://questionsmedicales.fr/author/Benjamin%20E%20Hilbig",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, RPTU Kaiserslautern-Landau, Fortstr. 7, 76829, Landau, Germany."
}
},
{
"@type": "Person",
"name": "Erich Seifritz",
"url": "https://questionsmedicales.fr/author/Erich%20Seifritz",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland."
}
},
{
"@type": "Person",
"name": "Adrien T Stanley",
"url": "https://questionsmedicales.fr/author/Adrien%20T%20Stanley",
"affiliation": {
"@type": "Organization",
"name": "Departments of Biology and Psychiatry, Columbia University, New York, NY, United States."
}
},
{
"@type": "Person",
"name": "David Sulzer",
"url": "https://questionsmedicales.fr/author/David%20Sulzer",
"affiliation": {
"@type": "Organization",
"name": "Departments of Psychiatry, Neurology, and Pharmacology, Columbia University Medical Center, New York, NY, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Myeloproliferative neoplasms in adolescents and young adults.",
"datePublished": "2022-08-14",
"url": "https://questionsmedicales.fr/article/36333071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.beha.2022.101374"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hypertriglyceridemia in young adults with a 22q11.2 microdeletion.",
"datePublished": "2022-05-19",
"url": "https://questionsmedicales.fr/article/35521712",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1530/EJE-21-1104"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adolescent and Young Adult Communication Preferences.",
"datePublished": "2022-11-16",
"url": "https://questionsmedicales.fr/article/36383117",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/jayao.2022.0087"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thoughts of young adults with Down syndrome.",
"datePublished": "2022-07-09",
"url": "https://questionsmedicales.fr/article/36428048",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.apnu.2022.06.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adrenal crises in adolescents and young adults.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35583847",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-022-03070-3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Disciplines et activités comportementales",
"item": "https://questionsmedicales.fr/mesh/D004191"
},
{
"@type": "ListItem",
"position": 3,
"name": "Psychothérapie",
"item": "https://questionsmedicales.fr/mesh/D011613"
},
{
"@type": "ListItem",
"position": 4,
"name": "Thérapie comportementale",
"item": "https://questionsmedicales.fr/mesh/D001521"
},
{
"@type": "ListItem",
"position": 5,
"name": "Thérapie aversive",
"item": "https://questionsmedicales.fr/mesh/D001348"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Thérapie aversive - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Thérapie aversive",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Thérapie aversive",
"description": "Comment diagnostiquer un besoin de thérapie aversive ?\nQuels tests sont utilisés pour évaluer les comportements ?\nQui peut prescrire une thérapie aversive ?\nQuels critères sont utilisés pour le diagnostic ?\nLa thérapie aversive est-elle adaptée à tous ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Thérapie aversive",
"description": "Quels symptômes indiquent un besoin de thérapie aversive ?\nComment se manifestent les comportements indésirables ?\nLes symptômes varient-ils selon les individus ?\nQuels effets émotionnels peuvent résulter de ces comportements ?\nLes symptômes physiques sont-ils liés à la thérapie aversive ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Thérapie aversive",
"description": "Comment prévenir les comportements indésirables ?\nLes interventions précoces sont-elles efficaces ?\nQuel rôle joue le soutien social dans la prévention ?\nLes programmes éducatifs sont-ils utiles ?\nComment la thérapie préventive est-elle mise en œuvre ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Thérapie aversive",
"description": "Comment fonctionne la thérapie aversive ?\nQuels types de stimuli sont utilisés ?\nLa thérapie aversive est-elle efficace ?\nCombien de séances sont généralement nécessaires ?\nY a-t-il des alternatives à la thérapie aversive ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Thérapie aversive",
"description": "Quelles complications peuvent survenir avec la thérapie aversive ?\nLa thérapie aversive peut-elle aggraver certains symptômes ?\nQuels sont les effets à long terme de cette thérapie ?\nComment gérer les complications éventuelles ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Thérapie aversive",
"description": "Quels facteurs augmentent le risque de comportements indésirables ?\nLe stress est-il un facteur de risque ?\nLes troubles mentaux prédisposent-ils à la thérapie aversive ?\nL'isolement social est-il un facteur de risque ?\nLes antécédents de traumatismes influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001348?mesh_terms=Young+Adult&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin de thérapie aversive ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un professionnel évalue les comportements problématiques et leur impact sur la vie quotidienne."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les comportements ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires et des entretiens cliniques sont souvent utilisés pour l'évaluation."
}
},
{
"@type": "Question",
"name": "Qui peut prescrire une thérapie aversive ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un psychologue ou un psychiatre qualifié peut prescrire cette thérapie après évaluation."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la fréquence et l'intensité des comportements indésirables."
}
},
{
"@type": "Question",
"name": "La thérapie aversive est-elle adaptée à tous ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle n'est pas recommandée pour tous les patients, surtout ceux avec des troubles graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin de thérapie aversive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements compulsifs ou des addictions peuvent nécessiter cette thérapie."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les comportements indésirables ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des actions répétitives nuisibles ou des dépendances."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'individu et de la situation."
}
},
{
"@type": "Question",
"name": "Quels effets émotionnels peuvent résulter de ces comportements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les individus peuvent ressentir de la honte, de l'anxiété ou de la dépression."
}
},
{
"@type": "Question",
"name": "Les symptômes physiques sont-ils liés à la thérapie aversive ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes physiques peuvent apparaître en raison du stress lié aux comportements."
}
},
{
"@type": "Question",
"name": "Comment prévenir les comportements indésirables ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation et la sensibilisation aux conséquences des comportements peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les interventions précoces sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions précoces peuvent réduire le développement de comportements problématiques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le soutien social dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bon soutien social peut aider à réduire les comportements indésirables en offrant des alternatives."
}
},
{
"@type": "Question",
"name": "Les programmes éducatifs sont-ils utiles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent sensibiliser aux risques et aux conséquences des comportements indésirables."
}
},
{
"@type": "Question",
"name": "Comment la thérapie préventive est-elle mise en œuvre ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut inclure des séances de groupe ou des ateliers sur la gestion des comportements."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la thérapie aversive ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle associe un comportement indésirable à un stimulus désagréable pour réduire ce comportement."
}
},
{
"@type": "Question",
"name": "Quels types de stimuli sont utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des stimuli tels que des sons désagréables ou des sensations physiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "La thérapie aversive est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être efficace pour certains comportements, mais les résultats varient selon les individus."
}
},
{
"@type": "Question",
"name": "Combien de séances sont généralement nécessaires ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le nombre de séances varie, mais plusieurs semaines sont souvent nécessaires pour des résultats."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives à la thérapie aversive ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches comme la thérapie cognitivo-comportementale peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la thérapie aversive ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications émotionnelles comme l'anxiété ou la dépression peuvent survenir."
}
},
{
"@type": "Question",
"name": "La thérapie aversive peut-elle aggraver certains symptômes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aggraver des symptômes chez certains patients sensibles ou vulnérables."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme de cette thérapie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure une réduction des comportements, mais aussi des effets négatifs."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications éventuelles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et un ajustement des techniques peuvent aider à gérer les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles ne sont pas systématiques, mais peuvent survenir selon la sensibilité du patient."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de comportements indésirables ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de troubles mentaux et un environnement stressant peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer au développement de comportements indésirables."
}
},
{
"@type": "Question",
"name": "Les troubles mentaux prédisposent-ils à la thérapie aversive ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles mentaux peuvent rendre la thérapie aversive plus nécessaire."
}
},
{
"@type": "Question",
"name": "L'isolement social est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'isolement social peut exacerber les comportements indésirables et les addictions."
}
},
{
"@type": "Question",
"name": "Les antécédents de traumatismes influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traumatismes passés peuvent augmenter la probabilité de comportements problématiques."
}
}
]
}
]
}
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders commonly diagnosed in the seventh decade of life. With increasing access to blood surveillance, the number of adolescent and young ad...
Mild to moderate hypertriglyceridemia is a condition often associated with obesity and diabetes, with as yet incomplete knowledge of underlying genetic architecture. The 22q11.2 microdeletion is assoc...
This was a cohort study comparing 6793 population-based adults and 267 with a 22q11.2 microdeletion aged 17-69 years, excluding those with diabetes or on statins....
We used binomial logistic regression modeling to identify predictors of hypertriglyceridemia, accounting for the 22q11.2 microdeletion, male sex, BMI, ethnicity, age, and antipsychotic medications....
The 22q11.2 microdeletion was a significant independent predictor of mild to moderate hypertriglyceridemia (odds ratio (OR): 2.35, 95% CI: 1.70-3.26). All other factors examined were also significant ...
The 22q11.2 microdeletion is associated with hypertriglyceridemia even when accounting for other known risk factors for elevated triglycerides. This effect is seen in young adulthood (76.6% were <40 y...
The purpose of this study was to examine adolescents and young adults preferred methods of communication by health care professionals and to identify whether this aligns/differs from overall preferred...
This study aimed to obtain information about the thoughts of young adults with Down syndrome through interviews of them....
The numbers of participants were 4 and 7 in order to group interviews and individual interviews. They were recruited through the local Association of Parents of Down syndrome. The study incorporated a...
Through analysis, six themes emerged: 1) thoughts about work, 2) existence of friends, 3) how to spend leisure time, 4) meaning of disability, 5) relationships with people, and 6) future dreams....
1) Although young adults with Down syndrome are serious about their work, it is difficult for them to make friends at work. However, they recognized people at work as their comrades and were encourage...
Review the literature concerning adrenal insufficiency (AI) and adrenal crisis (AC) in adolescents and young adults....
Searches of PubMed identifying relevant reports up to March 2022....
AI is rare disorder that requires lifelong glucocorticoid replacement therapy and is associated with substantial morbidity and occasional mortality among adolescents and young adults. Aetiologies in t...
In this review, we examine the current state of knowledge of AC epidemiology in emerging adults; examine the causes of ACs in this age group; and suggest areas for further investigation that are aimed...
Ischemic Stroke in young adults is a real public health problem; it's a major cause of disability, alters quality of life and has a great socio-economic impact....
determine risk factors and specify the etiology of arterial ischemic stroke in young Tunisian adults....
In this 5 years retrospective study (2015-2020), we included all young adults (18-50 years) admitted for arterial ischemic stroke (AIS). Risk factors were registered and analyzed. All patients were in...
We collected 200 patients with AIS. The mean age was 41.37 years ± 6.99. Traditional vascular risk factors were observed in more than 1⁄4 patients. A definite cause of stroke was identified in 120 pat...
Through this study, we demonstrated the diversity of etiology of stroke in young Tunisian adults. Changes of lifestyle are responsible for the occurrence of the traditional risk factors at an early ag...
Radiotherapy for adolescents and young adults is complex in several aspects. The population is very heterogeneous and has characteristics derived from both paediatric and adult populations both in ter...
Spontaneous pneumomediastinum is characterized by the accumulation of air in the mediastinum with no identified cause. It is a rare and self-limiting condition. We report the case of a 32-year-old fem...
Primary hyperparathyroidism (PHPT) affects 2% of Americans over 55 years of age, and is less common in younger patients. Pediatric PHPT patients have higher rates of multigland disease (MGD). We studi...
Retrospective chart review was performed on patients who underwent parathyroidectomy for PHPT (2000-2019). Cohorts were defined by age: Group A (18-40 years) and Group B (> 40 years). Univariate and m...
Of 3889 patients with PHPT, 9.1% (n = 352) were included in Group A. On multivariate analysis, multiple endocrine neoplasia (odds ratio [OR] 6.3, 95% confidence interval [CI] 3.1-12.7), male sex (OR 1...
In our population of patients with sporadic PHPT, a positive family history of PHPT was strongly associated with MGD; additional associations were found with prior parathyroidectomy, non-localizing im...
Developmental dysplasia of the hip (DDH) is one of the most common disorders of hips in children. The deformity can remain asymptomatic into adolescence and adulthood; however, it is considered to be ...